Profile data is unavailable for this security.
About the company
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidate includes JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr), being investigated in a Phase I clinical trial in adult subjects with metastatic castration-resistant prostate cancer (mCRPC). JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
- Revenue in USD (TTM)7.29m
- Net income in USD-55.59m
- Incorporated2017
- Employees64.00
- LocationJanux Therapeutics Inc10955 Vista Sorrento Parkway, Suite 200SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 751-4493
- Fax+1 (302) 655-5049
- Websitehttps://www.januxrx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Amphastar Pharmaceuticals Inc | 676.21m | 154.69m | 1.98bn | 1.76k | 13.95 | 2.94 | 9.85 | 2.93 | 2.90 | 2.90 | 12.70 | 13.77 | 0.576 | 2.79 | 5.66 | 383,991.50 | 13.33 | 9.42 | 15.75 | 11.56 | 54.73 | 47.83 | 23.14 | 15.23 | 1.72 | 8.48 | 0.4692 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
Rocket Pharmaceuticals Inc | 0.00 | -249.31m | 1.98bn | 268.00 | -- | 4.49 | -- | -- | -2.87 | -2.87 | 0.00 | 4.87 | 0.00 | -- | -- | 0.00 | -49.16 | -35.26 | -52.49 | -37.49 | -- | -- | -- | -- | -- | -- | 0.0458 | -- | -- | -- | -10.70 | -- | 62.52 | -- |
Novavax Inc | 996.61m | -398.71m | 2.02bn | 1.54k | -- | -- | -- | 2.03 | -3.18 | -3.18 | 8.46 | -6.18 | 0.6882 | 14.75 | 14.85 | 645,890.50 | -27.53 | -46.06 | -460.95 | -269.57 | 63.04 | -- | -40.01 | -75.94 | 0.8843 | -27.04 | -- | -- | -50.36 | 95.68 | 17.16 | -- | 108.28 | -- |
Kymera Therapeutics Inc | 79.41m | -154.59m | 2.04bn | 186.00 | -- | 2.87 | -- | 25.72 | -2.50 | -2.50 | 1.29 | 11.59 | 0.1072 | -- | 29.69 | 424,668.40 | -20.86 | -23.03 | -22.67 | -27.64 | -- | -- | -194.67 | -207.82 | -- | -- | 0.0032 | -- | 67.84 | -- | 5.07 | -- | 91.01 | -- |
Beam Therapeutics Inc | 360.91m | -134.74m | 2.05bn | 436.00 | -- | 2.24 | -- | 5.67 | -1.74 | -1.74 | 4.54 | 11.10 | 0.2681 | -- | -- | 827,777.50 | -10.01 | -24.54 | -11.79 | -29.26 | -- | -- | -37.33 | -211.96 | -- | -- | 0.00 | -- | 520.01 | -- | 54.16 | -- | 20.78 | -- |
Vericel Corp | 207.78m | 451.00k | 2.06bn | 314.00 | 4,423.64 | 8.77 | 380.62 | 9.89 | 0.0096 | 0.0096 | 4.35 | 4.82 | 0.6684 | 4.38 | 4.71 | 661,719.80 | 0.1451 | -3.07 | 0.1621 | -3.50 | 69.50 | 67.87 | 0.2171 | -4.49 | 4.83 | -- | 0.0007 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
Myriad Genetics, Inc. | 774.20m | -234.60m | 2.10bn | 2.70k | -- | 2.76 | -- | 2.71 | -2.82 | -2.82 | 9.11 | 8.40 | 0.6792 | 10.41 | 6.53 | 286,740.80 | -20.58 | -- | -23.57 | -- | 68.79 | -- | -30.30 | -- | 1.82 | -225.20 | 0.0485 | -- | 11.03 | -- | -135.09 | -- | -- | -- |
Amneal Pharmaceuticals Inc | 2.50bn | -168.69m | 2.13bn | 7.70k | -- | -- | 19.97 | 0.8523 | -0.5642 | -0.5642 | 11.52 | -0.2065 | 0.7046 | 2.94 | 4.11 | 324,059.50 | -3.40 | -4.80 | -4.27 | -5.93 | 35.28 | 34.76 | -4.82 | -9.00 | 0.97 | 1.27 | 1.01 | -- | 8.20 | 7.56 | 35.38 | -- | -6.55 | -- |
Fortrea Holdings Inc | 3.01bn | -100.60m | 2.14bn | 16.00k | -- | 1.35 | -- | 0.7127 | -1.13 | -1.37 | 33.82 | 17.81 | 0.7036 | -- | 3.10 | 167,050.00 | -2.35 | -- | -2.84 | -- | 16.64 | -- | -3.35 | -- | -- | 0.2534 | 0.5035 | -- | 0.4167 | -- | -101.76 | -- | -- | -- |
Janux Therapeutics Inc | 7.29m | -55.59m | 2.18bn | 64.00 | -- | 3.32 | -- | 298.85 | -1.22 | -1.22 | 0.159 | 12.65 | 0.014 | -- | 11.48 | 113,859.40 | -10.67 | -- | -10.95 | -- | -- | -- | -762.92 | -- | -- | -- | 0.00 | -- | -6.14 | -- | 7.56 | -- | -- | -- |
Recursion Pharmaceuticals Inc | 46.24m | -354.11m | 2.20bn | 500.00 | -- | 5.48 | -- | 47.60 | -1.62 | -1.62 | 0.2112 | 1.69 | 0.078 | -- | 19.86 | 92,470.00 | -59.76 | -- | -69.49 | -- | 10.66 | -- | -765.90 | -- | -- | -- | 0.0028 | -- | 11.88 | -- | -36.99 | -- | -- | -- |
Iovance Biotherapeutics Inc | 1.90m | -449.64m | 2.28bn | 557.00 | -- | 3.36 | -- | 1,199.28 | -1.82 | -1.82 | 0.0077 | 2.43 | 0.0023 | -- | -- | 3,418.31 | -53.07 | -51.47 | -59.00 | -57.56 | -846.22 | -- | -23,615.70 | -137,873.80 | 4.42 | -- | 0.0015 | -- | -- | -- | -12.16 | -- | 79.44 | -- |
Celldex Therapeutics, Inc. | 6.07m | -144.88m | 2.29bn | 160.00 | -- | 2.72 | -- | 376.34 | -2.84 | -2.84 | 0.1182 | 12.72 | 0.0102 | -- | 3.05 | 37,950.00 | -24.28 | -29.65 | -25.16 | -31.42 | -- | -- | -2,385.97 | -1,747.94 | -- | -- | 0.00 | -- | 192.02 | -6.32 | -25.91 | -- | 17.46 | -- |
Novocure Ltd | 525.66m | -192.74m | 2.30bn | 1.45k | -- | 6.39 | -- | 4.37 | -1.81 | -1.81 | 4.92 | 3.34 | 0.4579 | 3.57 | 7.51 | 361,774.90 | -16.79 | -7.74 | -19.40 | -8.95 | 74.82 | 77.22 | -36.67 | -14.69 | 5.99 | -- | 0.6132 | -- | -5.30 | 15.47 | -123.75 | -- | 32.19 | -- |
CG Oncology Inc | 539.00k | -72.33m | 2.31bn | 61.00 | -- | 4.06 | -- | 4,285.25 | -1.13 | -1.13 | 0.0084 | 8.54 | -- | -- | -- | 8,836.07 | -- | -- | -- | -- | -- | -- | -10,551.39 | -- | -- | -- | 0.00 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
RA Capital Management LPas of 31 Mar 2024 | 9.17m | 17.68% |
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 7.55m | 14.56% |
BVF Partners LPas of 31 Mar 2024 | 2.92m | 5.63% |
Adage Capital Management LPas of 31 Mar 2024 | 2.78m | 5.35% |
Citadel Advisors LLCas of 31 Mar 2024 | 2.31m | 4.46% |
Janus Henderson Investors US LLCas of 31 Mar 2024 | 1.95m | 3.77% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 1.53m | 2.95% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.33m | 2.56% |
RTW Investments LPas of 31 Mar 2024 | 1.00m | 1.93% |
Cormorant Asset Management LPas of 31 Mar 2024 | 750.00k | 1.45% |